The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.
 
Lipika Goyal
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Cogent Biosciences; Compass Therapeutics; Eisai/H3 Biomedicine; Exelixis; Genentech; Incyte; Kinnate Biopharma; Merck; QED Therapeutics; SERVIER; Sirtex Medical; Surface Oncology; Synthekine; Taiho Pharmaceutical; TransThera Biosciences; Tyra Biosciences
Research Funding - Alyssum (Inst); Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Agios; Boehringer Ingelheim; Boehringer Ingelheim; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Haley Ellis
No Relationships to Disclose
 
Mitesh Borad
No Relationships to Disclose
 
Richard Kim
Honoraria - Natera
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Eisai; Exelixis; Jazz Pharmaceuticals; Pfizer; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - AstraZeneca; Incyte
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Alexander Starodub
No Relationships to Disclose
 
Juan Valle
Consulting or Advisory Role - AstraZeneca; Cogent Biosciences (Inst); Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals (Inst); Oncosil (Inst); Owkin (Inst); Redx Pharma (Inst); SERVIER; Taiho Oncology
 
John Bridgewater
No Relationships to Disclose
 
Jeffery Russell
No Relationships to Disclose
 
Akza Ali
Honoraria - Tersera
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Guardant Health; Guardant Health
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Symbiosys
Travel, Accommodations, Expenses - Tersera
 
Kevin Moynihan
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Meredith Little
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Liangxing Zou
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Julia Lawrence
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Arndt Vogel
Honoraria - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; EISAI; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche